See more : Elevate Uranium Ltd (EL8.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Centogene N.V. (CNTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Centogene N.V., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- SRV Yhtiöt Oyj (SRV1V.HE) Income Statement Analysis – Financial Results
- Mount Gibson Iron Limited (MTGRY) Income Statement Analysis – Financial Results
- Sunday Co.,Ltd. (7450.T) Income Statement Analysis – Financial Results
- ACTEOS S.A. (EOS.PA) Income Statement Analysis – Financial Results
- Puyi Inc. (PUYI) Income Statement Analysis – Financial Results
Centogene N.V. (CNTG)
About Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.54M | 47.47M | 189.92M | 128.38M | 48.78M | 40.48M | 31.69M | 27.67M |
| Cost of Revenue | 35.93M | 27.71M | 161.77M | 86.38M | 26.01M | 19.94M | 14.94M | 12.86M |
| Gross Profit | 11.61M | 19.76M | 28.16M | 42.00M | 22.78M | 20.54M | 16.75M | 14.81M |
| Gross Profit Ratio | 24.42% | 41.63% | 14.83% | 32.72% | 46.69% | 50.74% | 52.86% | 53.54% |
| Research & Development | 10.17M | 17.49M | 19.30M | 14.94M | 9.59M | 6.30M | 6.40M | 5.89M |
| General & Administrative | 29.17M | 29.21M | 44.79M | 37.67M | 23.16M | 18.61M | 9.50M | 8.89M |
| Selling & Marketing | 12.56M | 9.92M | 9.86M | 7.58M | 9.25M | 7.47M | 5.90M | 5.36M |
| SG&A | 41.68M | 39.13M | 54.65M | 45.25M | 32.41M | 26.08M | 15.40M | 14.25M |
| Other Expenses | 1.91M | -340.00K | -970.00K | -2.22M | 109.00K | -2.14M | 0.00 | 290.51K |
| Operating Expenses | 49.93M | 56.28M | 72.98M | 57.96M | 42.11M | 30.25M | 21.28M | 19.21M |
| Cost & Expenses | 85.86M | 83.99M | 234.74M | 144.34M | 68.12M | 50.19M | 36.22M | 32.07M |
| Interest Income | 209.00K | 3.00K | 3.00K | 6.00K | 16.00K | 33.00K | 14.00K | 26.00K |
| Interest Expense | 8.20M | 3.57M | 851.00K | 1.04M | 2.03M | 1.08M | 1.02M | 829.00K |
| Depreciation & Amortization | 7.45M | 10.19M | 20.77M | 14.09M | 6.56M | 5.34M | 3.04M | 2.19M |
| EBITDA | -30.87M | -26.00M | -41.03M | -50.12M | -12.74M | -5.40M | -1.29M | -2.94M |
| EBITDA Ratio | -64.93% | -54.77% | -12.39% | -0.64% | -26.12% | -11.12% | -4.04% | -8.28% |
| Operating Income | -38.32M | -36.52M | -44.82M | -15.96M | -19.34M | -10.61M | -4.46M | -4.94M |
| Operating Income Ratio | -80.61% | -76.92% | -23.60% | -12.43% | -39.64% | -26.20% | -14.06% | -17.84% |
| Total Other Income/Expenses | 3.08M | -1.82M | -4.22M | 32.63M | -1.36M | -1.94M | -1.01M | -741.00K |
| Income Before Tax | -34.23M | -38.60M | -46.88M | -21.10M | -20.70M | -11.65M | -5.46M | -5.77M |
| Income Before Tax Ratio | -71.99% | -81.30% | -24.68% | -16.43% | -42.43% | -28.78% | -17.24% | -20.84% |
| Income Tax Expense | 281.12K | 107.00K | -24.00K | 281.00K | 158.00K | -310.00K | 14.00K | -408.00K |
| Net Income | -34.80M | -38.70M | -46.85M | -21.38M | -20.86M | -11.34M | -5.48M | -5.36M |
| Net Income Ratio | -73.21% | -81.53% | -24.67% | -16.65% | -42.75% | -28.01% | -17.28% | -19.37% |
| EPS | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| EPS Diluted | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| Weighted Avg Shares Out | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
| Weighted Avg Shares Out (Dil) | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
Citi cuts view on Illumina in premarket analyst action
Centogene Reports Financial Results For Full Year 2019 and Highlights Recent Progress
Centogene (NASDAQ:CNTG) vs. Guardant Health (NASDAQ:GH) Financial Analysis
Analyzing Laboratory Corp. of America (NYSE:LH) and Centogene (NYSE:CNTG)
Coronavirus Scare Supports These Biotech ETFs & Stocks
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
Source: https://incomestatements.info
Category: Stock Reports